All news

Director Helen Collins plans to sell 15,000 Enliven Therapeutics (ELVN) shares.

Alpha Vantage · Stock Titan · · AI-summarised by FinFlash

Enliven Therapeutics director Helen Collins has filed notice to sell 15,000 common shares of ELVN, valued at $559,800, with an approximate sale date of October 19, 2026. This proposed sale is being conducted under a Rule 10b5-1 plan adopted on October 19, 2025. The filing also indicates previous sales of 5,000 shares each on August 17, 2026, and September 17, 2026.

Read original source

ELVN company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.